Ankle arthrodesis: rhPDGF-BB/TCP is an effective and safe alternative to autograft .
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Recombinant Human Platelet-Derived Growth Factor-BB and Beta-Tricalcium Phosphate (rhPDGF-BB/B-TCP): An Alternative to Autogenous Bone Graft
J Bone Joint Surg Am. 2013 Jul 3;95(13):1184-92. doi: 10.2106/JBJS.K.01422Four hundred and thirty four patients in need of either an ankle or hindfoot arthrodesis were randomized to undergo the procedure using either the recombinant human (rh) PDGF-BB/TCP or autograft as bone fusion promoters to determine the non-inferiority of rhPDGF-BB/TCP. Results indicated that rhPDGF-BB/TCP proved to be non-inferior to autograft with respect to fusion rates, clinical union, radiographic union, pain, quality of life, and functional outcomes. Furthermore, rhPDGF-BB/TCP was equally, if not more, safe compared to autograft, with no significant differences between the two groups in terms of complications and adverse events.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
